Skip to main content

Research

The latest research in type 1 diabetes, type 2 diabetes, prediabetes, and beyond. Here you’ll find information on experimental therapies, new data and results, and scientific findings.

Results from the CREDENCE trial suggest that Invokana’s kidney benefits exist on top of blood pressure lowering medications (standard of care)
Why it’s a big deal for the closed loop and pump fields, when it might be available, and how Tidepool is working with the FDA and companies to make it happen
The EMA approved Zynquista (sotagliflozin), an SGLT-1/2 dual inhibitor, for adults with a BMI above 27
Surprising study findings from a look at refrigerator temperatures and the risk posed to insulin quality; plus, a guide to safe insulin storage and Med Angel’s very cool...
Big focus on heart health outcome trials with PIONEER 6 and CAROLINA in the spotlight; plus promising CGM data in adolescents with type 1 diabetes
Recently announced results from the REWIND and EMPRISE studies show heart protective effects of GLP1-agonist Trulicity and SGLT-2 inhibitor Jardiance in people with and...
The first GLP-1 pill for type 2 diabetes offers weight loss and A1C reduction without injections; US decision expected in September 2019, EU decision expected spring of...
FDA updates Invokana label – the type 2 diabetes therapy now improves heart health in type 2’s with established heart disease in addition to glucose lowering
Virta’s program resulted in “reversal” of type 2 diabetes in 54% of participants after two years. Data show 10% bodyweight loss, 0.9% A1C reduction, and reduced need for...
Farxiga and Zynquista are recommended for approval for people with type 1 diabetes in Europe with emphasis on DKA safety; EMA approval likely in coming months and hope...
From clinical expertise and personal experience as a type 1, Dr. Sherr shares valuable (and exciting) perspectives on diabetes treatments.
Amarin’s Vascepa, an omega-3 fatty acid, is shown to lower risk of heart attack, stroke, and heart-related death for adults with high risk for heart disease with...
A collaboration between JDRF, Stanford, and UCSF aims to cure type 1 diabetes through understanding of stem cells and the immune system
The diaTribe team was in Barcelona for the 55 th Annual Meeting of the European Association for the Study of Diabetes. Check out our biggest highlights from the...
By Ursula Biba and Eliza Skoler The new State of Childhood Obesity report and website show that youth obesity is prevalent in the US, leading to high rates of adult...
Will the medication move from “off label” to standard of care for people at high risk of developing type 2 diabetes?
As we demand more nutritious and sustainable food, big food companies must make adjustments to their products, practices, and marketing
A new paper suggests that as people with diabetes increase their time in range, healthcare costs decrease
Control-IQ the first AID system with automatic correction boluses and no fingersticks CGM (Dexcom G6); cleared for those ages 14 and older; launch in January 2020
Farxiga’s heart health benefits were the same in people with and without diabetes, as well as across a spectrum of baseline A1C levels

Pages